Er Her2 Ve Breast Cancer Pipeline Insight
DelveInsight’s, “ER+/ HER2-VE Breast Cancer - Pipeline Insight, 2022,” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in ER+/ HER2-VE Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
ER+/ HER2-VE Breast Cancer Understanding
ER+/ HER2-VE Breast Cancer: Overview
HR+ breast cancers are those that express estrogen receptors (ER) or progesterone receptors (PR) or both. These tumors account for 70–80% of all breast cancers. These hormone-dependent cancers can often be treated successfully with a variety of drugs that modulate ER or reduce estrogen.
HER2 is short for human epidermal growth factor receptor. HER2 is sometimes called ERBB2, which stands for Erb-B2 receptor tyrosine kinase. HER2 is a gene that produces HER2 proteins, or receptors. If breast cancer cells don’t have abnormal levels of HER2 proteins, the breast cancer is considered HER2-negative.
The companies and academics are working to assess challenges and seek opportunities that could influence ER+/ HER2-VE Breast Cancer R&D. The therapies under development are focused on novel approaches for ER+/ HER2-VE Breast Cancer.
ER+/ HER2-VE Breast Cancer Emerging Drugs Chapters
This segment of the ER+/ HER2-VE Breast Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
ER+/ HER2-VE Breast Cancer Emerging Drugs
AZD-9833 acts as selective estrogen receptor degraders. It is being developed as combination therapy with palbociclib (a CDK4/6 inhibitor). It is currently in Phase III stage of dvelopement and is being developed by Astrazeneca.
Pamiparib (BGB-290) is an investigational small molecule inhibitor of PARP1 and PARP2. Pamiparib is being evaluated for the treatment of HER2 Negative Breast Cancer. Pamiparib is being evaluated as a monotherapy in pivotal clinical trials in China in recurrent platinum-sensitive and BRCA1/2 mutated ovarian cancers. It is currently in global clinical development as a monotherapy, and in combination with other agents, including BeiGene’s investigational anti-PD1 antibody, tislelizumab (BGB-A317), for a variety of solid tumor malignancies. It is currently in Phase II stage of development for HER2-Negative Breast Cancer and is being developed by Beigene.
Further product details are provided in the report……..
ER+/ HER2-VE Breast Cancer: Therapeutic Assessment
This segment of the report provides insights about the different ER+/ HER2-VE Breast Cancer drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on ER+/ HER2-VE Breast Cancer
There are approx. 40+ key companies which are developing the ER+/ HER2-VE Breast Cancer. The companies which have their ER+/ HER2-VE Breast Cancer drug candidates in the most advanced stage, i.e. Phase III include, Astrazeneca.
DelveInsight’s report covers around 50+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
ER+/ HER2-VE Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
ER+/ HER2-VE Breast Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses ER+/ HER2-VE Breast Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging ER+/ HER2-VE Breast Cancer drugs.
ER+/ HER2-VE Breast Cancer Report Insights
- ER+/ HER2-VE Breast Cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
ER+/ HER2-VE Breast Cancer Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing ER+/ HER2-VE Breast Cancer drugs?
- How many ER+/ HER2-VE Breast Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for ER+/ HER2-VE Breast Cancer?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the ER+/ HER2-VE Breast Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for ER+/ HER2-VE Breast Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?